|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
MA44729A
(fr)
|
2016-04-18 |
2021-05-12 |
Novartis Ag |
Composés et compositions pour traiter des états associés à une activité de nlrp
|
|
UA126675C2
(uk)
|
2017-01-23 |
2023-01-11 |
Дженентек, Інк. |
Хімічні сполуки як інгібітори активності інтерлейкіну-1
|
|
US11840543B2
(en)
|
2017-05-24 |
2023-12-12 |
The University Of Queensland |
Compounds and uses
|
|
CN110914256A
(zh)
|
2017-07-07 |
2020-03-24 |
英夫拉索姆有限公司 |
新颖磺酰胺羧酰胺化合物
|
|
EP3649112A1
(en)
|
2017-07-07 |
2020-05-13 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
JP7412328B2
(ja)
*
|
2017-07-24 |
2024-01-12 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
US11370763B2
(en)
|
2017-07-24 |
2022-06-28 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
TW201910317A
(zh)
*
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
CN111315733A
(zh)
*
|
2017-11-09 |
2020-06-19 |
英夫拉索姆有限公司 |
新颖磺酰胺甲酰胺化合物
|
|
GB201803394D0
(en)
*
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
US11834433B2
(en)
|
2018-03-02 |
2023-12-05 |
Inflazome Limited |
Compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
US12168653B2
(en)
|
2018-03-02 |
2024-12-17 |
Inflazome Limited |
Sulfonamide derivates as NLRP3 inhibitors
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
CR20200588A
(es)
|
2018-05-04 |
2021-06-24 |
Inflazome Ltd |
Compuestos novedosos
|
|
JP2021529187A
(ja)
*
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐモジュレータ
|
|
US20210395241A1
(en)
*
|
2018-07-03 |
2021-12-23 |
Novartis Ag |
Nlrp modulators
|
|
JP2021529780A
(ja)
|
2018-07-03 |
2021-11-04 |
ノバルティス アーゲー |
Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
|
|
MX2021000660A
(es)
|
2018-07-20 |
2021-03-25 |
Hoffmann La Roche |
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
|
|
MA53172A
(fr)
|
2018-07-20 |
2021-05-26 |
Hoffmann La Roche |
Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
|
|
SG11202101480XA
(en)
|
2018-08-15 |
2021-03-30 |
Inflazome Ltd |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
US20230011652A1
(en)
*
|
2018-10-24 |
2023-01-12 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CR20210235A
(es)
|
2018-11-13 |
2021-06-30 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
|
|
CN113166081A
(zh)
|
2018-11-13 |
2021-07-23 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
CN113015730A
(zh)
*
|
2018-11-13 |
2021-06-22 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
EP3880658A1
(en)
*
|
2018-11-16 |
2021-09-22 |
Novartis AG |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
AU2020210117B2
(en)
|
2019-01-14 |
2025-03-13 |
Zydus Lifesciences Limited |
Novel substituted sulfonylurea derivatives
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN111848461A
(zh)
*
|
2019-04-29 |
2020-10-30 |
苏州大学 |
Nlrp3炎症小体抑制剂及其制备方法和应用
|
|
CA3141407A1
(en)
*
|
2019-06-17 |
2020-12-24 |
Charles A. Dinarello |
Method for treating asthma
|
|
CN114008030A
(zh)
|
2019-06-21 |
2022-02-01 |
Ac免疫有限公司 |
用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
AU2020312800B2
(en)
*
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
WO2021009567A1
(en)
|
2019-07-17 |
2021-01-21 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
JP2022545400A
(ja)
|
2019-08-16 |
2022-10-27 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
CN111100042B
(zh)
*
|
2019-11-18 |
2022-05-31 |
苏州诚和医药化学有限公司 |
一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
|
|
CN111018750B
(zh)
*
|
2019-12-19 |
2022-05-27 |
苏州诚和医药化学有限公司 |
一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
|
|
BR112022014480A2
(pt)
|
2020-01-22 |
2022-09-13 |
Hoffmann La Roche |
Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
US20230121952A1
(en)
|
2020-02-18 |
2023-04-20 |
Inflazome Limited |
Compounds
|
|
CA3175729A1
(en)
*
|
2020-03-16 |
2021-09-23 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
US20230146308A1
(en)
|
2020-03-19 |
2023-05-11 |
Softhale Nv |
Method for the treatment nlrp3-associated diseases
|
|
CN115768749B
(zh)
*
|
2020-06-11 |
2024-04-19 |
辰欣药业股份有限公司 |
二甲基亚磺酰亚胺衍生物
|
|
US12624010B2
(en)
|
2020-06-19 |
2026-05-12 |
Ac Immune Sa |
Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
CN117279903A
(zh)
*
|
2021-02-10 |
2023-12-22 |
杭州英创医药科技有限公司 |
作为nlrp3抑制剂的化合物
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116635374B
(zh)
*
|
2021-05-10 |
2025-05-06 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
WO2023098612A1
(zh)
*
|
2021-12-03 |
2023-06-08 |
南京明德新药研发有限公司 |
二甲基亚磺酰亚胺衍生物的盐型及晶型
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
WO2024023266A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
Novel compounds
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
AU2024280075A1
(en)
|
2023-06-02 |
2025-12-11 |
Merck Sharp & Dohme Llc |
5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
TW202545527A
(zh)
|
2024-01-16 |
2025-12-01 |
英商諾得瑟拉公司 |
Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
|
|
CN122555707A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
CN122555708A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|
|
WO2026132518A1
(en)
|
2024-12-20 |
2026-06-25 |
Ac Immune Sa |
Heterocyclic compounds modulating the nlrp3 inflammasome pathway
|